Botanix Pharmaceuticals Ltd (ASX: BOT) Share Price and News

Price

Movement

( )

(20 mins delayed)

52 Week Range

-

 
1 Year Return

 

Botanix Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $889.04 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 1.95 billion
Earnings per share -0.022
Dividend per share N/A
Year To Date Return 2.30%
Earnings Yield N/A
Franking -
Share Price

Day Change

( )

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

Botanix Pharmaceuticals Ltd (ASX: BOT)
Latest News

rocketing asx share price represented by man riding golden dollar sign speeding through clouds
Share Market News

Why the Botanix (ASX:BOT) share price rocketed 22% to a record high today

The Botanix Pharmaceuticals Ltd (ASX:BOT) share price is rocketing higher again on Wednesday. Here's why it hit a record high...

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Share Market News

Why the Botanix (ASX:BOT) share price is soaring up today

The Botanix (ASX: BOT) share price is surging higher today on news the company has completed its phase 2a clinical…

Read more »

Share Market News

Why the Botanix (ASX:BOT) share price is 15% higher today

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price shot up 15% higher today on news of a positive update in…

Read more »

Share Market News

The Botanix (ASX:BOT) share price is soaring 15% higher today. Here's why.

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price is soaring higher today following the release of its September quarter update.

Read more »

soaring hydrix share price represented by doctor riding on top of heart high up in the clouds
Investing

Why I think these small cap ASX shares will perform in 2021

The ASX is littered with lots of companies that show potential to become the next market darling. Here are my…

Read more »

Share Market News

This ASX cannabis share just hit a milestone

The Botanix share price surged 20% higher today following the company's announcement of a milestone achievement but has since been…

Read more »

a woman
Share Market News

What's in store for these 4 ASX cannabis shares in 2020?

2019 was a bear market for cannabis stocks globally. We take a look at what 2020 holds for ASX cannabis…

Read more »

a woman
Healthcare Shares

How did these ASX cannabis shares perform in 2019?

This year was a difficult one for ASX cannabis shares as well as cannabis stocks globally with share prices worldwide…

Read more »

a woman
Share Gainers

Why these ASX cannabis shares are starting the week on a high

Cannabis shares AusCann Group Holdings Ltd (ASX:AC8) and Botanix Pharmaceuticals Ltd (ASX:BOT) are on a high on Monday. Here's why...

Read more »

a woman
Share Market News

Which ASX cannabis shares should you buy in November?

Marijuana shares were hot favourites earlier this year but have suffered as investors revaluate the sector. Here we look at…

Read more »

a woman
Share Market News

The cannabis collapse: ASX marijuana shares going cheap

Investors have pulled back from marijuana shares as the sector begins to mature and the adverse publicity surrounding vaping takes…

Read more »

a woman
Share Fallers

Why Botanix, Elixinol Global, Pro Medicus, & Tinybeans shares tumbled lower

The Botanix Pharmaceuticals Ltd (ASX:BOT) share price and the Pro Medicus Limited (ASX:PME) share price are two of four tumbling…

Read more »

BOT ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Botanix Pharmaceuticals Ltd

Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1204 - Atopic Dermatitis, and BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is Derived from Australia.

BOT Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
02 May 2025 $0.46 $0.01 2.25% 10,253,453 $0.45 $0.47 $0.44
01 May 2025 $0.45 $-0.01 -2.22% 9,919,533 $0.46 $0.46 $0.42
30 Apr 2025 $0.45 $0.01 2.27% 10,890,639 $0.45 $0.46 $0.43
29 Apr 2025 $0.44 $0.04 9.88% 7,963,814 $0.41 $0.45 $0.41
28 Apr 2025 $0.41 $-0.02 -4.76% 5,983,154 $0.43 $0.44 $0.41
24 Apr 2025 $0.42 $-0.01 -2.35% 10,701,984 $0.42 $0.44 $0.40
23 Apr 2025 $0.43 $0.03 7.59% 6,938,022 $0.41 $0.43 $0.41
22 Apr 2025 $0.40 $0.00 0.00% 4,690,366 $0.40 $0.41 $0.39
17 Apr 2025 $0.40 $0.01 2.60% 5,382,654 $0.39 $0.40 $0.38
16 Apr 2025 $0.39 $0.01 2.67% 8,690,711 $0.38 $0.39 $0.37
15 Apr 2025 $0.38 $0.02 5.63% 16,096,668 $0.36 $0.40 $0.36
11 Apr 2025 $0.36 $-0.02 -5.41% 6,543,237 $0.37 $0.37 $0.35
10 Apr 2025 $0.37 $0.02 5.71% 12,841,932 $0.42 $0.42 $0.37
09 Apr 2025 $0.35 $-0.02 -5.41% 14,651,649 $0.36 $0.37 $0.34
08 Apr 2025 $0.37 $0.01 2.78% 9,900,873 $0.37 $0.38 $0.36
07 Apr 2025 $0.36 $-0.04 -10.00% 22,058,309 $0.38 $0.38 $0.34
04 Apr 2025 $0.40 $-0.03 -7.06% 7,860,709 $0.42 $0.42 $0.40
03 Apr 2025 $0.43 $-0.02 -4.55% 6,314,483 $0.44 $0.44 $0.41

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
20 Mar 2025 Daniel Sharp Exercise 4,000,000 $1,740,000
Exercise of options.
20 Mar 2025 Daniel Sharp Issued 3,111,145 $1,353,348
Exercise of options.
27 Feb 2025 Stewart Washer Issued 3,990,099 $1,815,495
Exercise of options.
27 Feb 2025 Stewart Washer Exercise 5,000,000 $2,275,000
Exercise of options.
15 Jan 2025 Vince Ippolito Sell 3,800,000 $1,672,000
On-market trade.
08 Jan 2025 Vince Ippolito Exercise 8,000,000 $3,680,000
Conversion of securities. 16,000,000 - Performance Rights
08 Jan 2025 Vince Ippolito Buy 8,000,000 $3,680,000
Conversion of securities.
07 Jan 2025 Vince Ippolito Transfer 10,801,644 $4,158,632
Off-market transfer. 10,801,644 Fully Paid Ordinary Shares were moved off
market
07 Jan 2025 Vince Ippolito Transfer 10,801,644 $4,158,632
Off-market transfer. 10,801,644 Fully Paid Ordinary Shares were moved off
market
02 Dec 2024 Matthew (Matt) Callahan Issued 3,000,000 $1,050,000
Issue of securities. 3,000,000 Performance Right
02 Dec 2024 Stewart Washer Issued 3,000,000 $1,050,000
Issue of securities. 3,333,333 Rights
02 Dec 2024 H. William Bosch Issued 3,000,000 $1,050,000
Issue of securities. 3,000,000 Performance Rights
02 Dec 2024 Vince Ippolito Issued 24,000,000 $8,400,000
Issue of securities. 24,000,000 Performance Rights
02 Dec 2024 Daniel Sharp Issued 3,000,000 $1,050,000
Issue of securities. 3,333,333 Rights

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Matthew (Matt) Callahan Executive Director Feb 2020
Mr Callahan is a life sciences executive based in Philadelphia and a founder of Botanix. He has been the founding CEO or Executive Director of a number of ASX listed and private pharmaceutical and health tech companies, including iCeutica Inc, Churchill Pharmaceuticals LLC, Dimerix Biosciences Ltd, Orthocell Ltd, Respirion Pharmaceuticals Pty Ltd, Rumin8 Pty Ltd and Emyria Ltd. Mr Callahan has led the development and commercialization of several products that have received FDA and other global regulatory approvals, he has more than 25 years of industry, IP and legal experience.
Dr Stewart James Washer Non-Executive Director Feb 2019
Dr Washer has CEO and board experience in medical biotech and device companies. Dr Washer chaired Hatchtech Pty Ltd that was sold in 2015 for A$279m and was a director of iCeutica that was sold to US private equity investors in 2010. He has been a Senator with Murdoch University and a director of AusBiotech Ltd.
Dr H. William Bosch Non-Executive Director Jul 2023
Dr Bosch is a pharmaceutical executive with more than 30 years of experience and industry leadership in pharmaceutical R&D. Dr. Bosch served as CSO of iCeutica where he was the principal architect of SoluMatrix drug delivery technology, used in four FDA-approved prescription drug products. Earlier in his career Dr Bosch was a creator in the application of nanotechnology to pharmaceutical product development. He served as a co-founder of NanoSystems LLC in 1995 and co-inventor of NanoCrystal Technology, leading to the development and FDA approval of seven prescription drug products for a variety of indications and routes of administration.
Mr Vince Ippolito PresidentExecutive ChairmanExecutive Director May 2019
Mr Ippolito has more than 35 years of experience in the pharmaceuticals industry, including over 20 years of experience in dermatology. He most recently served as President and Chief Operating Officer of Dermavant Sciences, a specialty biopharmaceutical company that is commercialising products which treat inflammatory skin diseases and medical dermatologic conditions. Prior to his role at Dermavant Sciences, Mr Ippolito served as the Chief Commercial Officer and Executive Vice President of Anacor Pharmaceuticals, a dermatology-based biopharmaceutical company.
Mr Daniel Sharp Non-Executive Director Mar 2022
Mr Sharp is an investment banker with more than 30 years of experience in capital markets globally, advising the boards of technology and healthcare-based organisations. He also has experience in sourcing and servicing both of institutional and private wealth investors globally. Mr Sharp was a Corporate Finance Executive Director of Canaccord Genuity for 8 years and previously spearheaded the Corporate Finance departments at both Shaw and Partners and Lodge Partners.
Ms Susan Patricia Park Company Secretary Apr 2023
-
Dr Howie McKibbon Chief Executive Officer Aug 2023
-
Howie McKibbon Chief Executive Officer
-
Graeme Morissey Chief Financial Officer
-
Susan Patricia Park Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Citicorp Nominees Pty Limited 158,445,435 8.73%
National Nominees Limited 111,876,013 6.17%
J P Morgan Nominees Australia Pty Limited 99,001,452 5.46%
Shenasaby Investments Pty Ltd <The Shenasaby A/C> 73,420,124 4.05%
UBS Nominees Pty Ltd 53,608,927 2.96%
Caperi Pty Ltd <Caperi A/C> 52,573,784 2.90%
Hsbc Custody Nominees (Australia) Limited 47,689,862 2.63%
BNP Paribas Nominees Pty Ltd <Agency Lending A/C> 34,339,755 1.89%
BNP Paribas Nominees Pty Ltd<Ib Au Noms Retailclient> 25,783,783 1.42%
Zenith Pacific Limited 22,272,222 1.23%
Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> 20,067,318 1.11%
Dr Henry William Bosch 18,836,702 1.04%
Yarraandoo Pty Ltd <Yarraandoo Super Fund A/C> 15,166,667 0.84%
Moffatt Investments Pty Ltd <Matthew Moffatt Family A/C> 12,378,182 0.68%
Rollo Corp Property Holdings Pty Ltd <Rollo Corp Property A/C> 10,930,000 0.60%
Mr Vincent Peter Ippolito 10,801,644 0.60%
BNP Paribas Noms Pty Ltd 9,542,034 0.53%
UBS Nominees Pty Ltd i 9,523,810 0.53%
Netwealth Investments Limited <Wrap Services A/C> 8,277,790 0.46%
Mr Nicolas Stephane Fayd'Herbe <Fayd'Herbe Family A/C> 7,888,032 0.43%

Profile

since

Note